Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Orcinol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 4/20 | 0.46 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.75 |
| ▸ | BACE1 | P56817 | 1/20 | 0.53 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.50 |
| ▸ | SELL | P14151 | 1/20 | 0.45 |
| ▸ | SELP | P16109 | 1/20 | 0.45 |
| ▸ | SELE | P16581 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Orcinol SCHEMBL8111445 | 0.97 | ALDH1A1 (0.71) | ALDH1A1BACE1HCAR1ACHESELL | |
| Orcinol SCHEMBL68497 | 0.93 | — | — | |
| Orcinol SCHEMBL7591999 | 0.90 | ALDH1A1 (0.80) | ALDH1A1BACE1HCAR1ACHESELL | |
| Orcinol SCHEMBL11445808 | 0.90 | ALDH1A1 (0.80) | ALDH1A1BACE1HCAR1ACHESELL | |
| Orcinol SCHEMBL7894743 | 0.90 | — | — | |
| Orcinol SCHEMBL236740 | 0.90 | ALDH1A1 (0.80) | ALDH1A1BACE1HCAR1ACHESELL | |
| Orcinol SCHEMBL11786364 | 0.90 | ALDH1A1 (0.80) | ALDH1A1BACE1HCAR1ACHESELL | |
| Orcinol SCHEMBL1886756 | 0.87 | ALDH1A1 (0.75) | ALDH1A1BACE1HCAR1ACHESELL | |
| Phloroglucinol SCHEMBL28465719 | 0.86 | ALDH1A1 (0.86) | ALDH1A1BACE1HCAR1ACHESELL | |
| SCHEMBL11574035 | 0.86 | ALDH1A1 (1.00) | ALDH1A1BACE1HCAR1ACHESELL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3748073-A1 | SEMI-BLEACHED OR UNBLEACHED EUCALYPTUS GLOBULUS PULP FOR TISSUE PRODUCTS | Raiz - Instituto De Investigação Da Floresta E Papel (PT) | 2020-12-09 | — | — | EP | disclosed |
| EP-3748077-A1 | EUCALYPTUS GLOBULUS BARK PULP FOR TISSUE PRODUCTS | Raiz - Instituto De Investigação Da Floresta E Papel (PT) | 2020-12-09 | — | — | EP | disclosed |
| US-7939057-B2 | Methods and compositions for modulating the mobilization of stem cells | MOUNT SINAI SCHOOL OF MEDICINE (US) | 2011-05-10 | — | — | US | disclosed |
| WO-2007087367-A9 | METHODS AND COMPOSITIONS FOR MODULATING THE MOBILIZATION OF STEM CELLS | SINAI SCHOOL MEDICINE (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070190023-A1 | Methods and compositions for modulating the mobilization of stem cells | MOUNT SINAI SCHOOL OF MEDICINE | 2007-08-16 | — | — | US | disclosed |
| WO-2007087367-A2 | METHODS AND COMPOSITIONS FOR MODULATING THE MOBILIZATION OF STEM CELLS | MOUNT SINAI SCHOOL OF MEDICINE (US) | 2007-08-02 | — | — | WO | disclosed |
| US-7220563-B2 | Glucose 6-oxidases | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2007-05-22 | — | — | US | disclosed |
| EP-1485404-A4 | NOVEL GLUCOSE 6-OXIDASES | CALIFORNIA INST OF TECHN (US) | 2005-03-30 | — | — | EP | disclosed |
| US-20050055748-A1 | Stress-responsive genes, regulatory elements, and methods of use for same | PIONEER HI-BRED INTERNATIONAL, INC. | 2005-03-10 | — | — | US | disclosed |
| EP-1485404-A2 | NOVEL GLUCOSE 6-OXIDASES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2004-12-15 | — | — | EP | disclosed |
| US-6830895-B2 | Kit for use in the classification of mammalian blood | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION | 2004-12-14 | — | — | US | disclosed |
| US-20030228673-A1 | Comprises genetically engineeered oxidoreductase having improved capability to oxidize secondary alcohols and/or D-glucose for use as quality control agents in dairy industry; biosensors in food processing | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2003-12-11 | — | — | US | disclosed |
| WO-2003072742-A2 | NOVEL GLUCOSE 6-OXIDASES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2003-09-04 | — | — | WO | disclosed |
| US-20030092088-A1 | Method and kit for typing feline blood | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION | 2003-05-15 | — | — | US | disclosed |
| WO-2003012444-A1 | METHOD AND KIT FOR TYPING FELINE BLOOD | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2003-02-13 | — | — | WO | disclosed |
| EP-0586687-A4 | TRANS-SIALIDASE AND METHODS OF USE AND MAKING THEREOF | UNIV NEW YORK (US) | 1996-04-17 | — | — | EP | disclosed |
| EP-0586687-A1 | TRANS-SIALIDASE AND METHODS OF USE AND MAKING THEREOF | NEW YORK UNIVERSITY (US) | 1994-03-16 | — | — | EP | disclosed |
| WO-1993018787-A1 | TRANS-SIALIDASE AND METHODS OF USE AND MAKING THEREOF | NEW YORK UNIVERSITY (US) | 1993-09-30 | — | — | WO | disclosed |
| WO-1989004670-A1 | PROCESS FOR PRODUCING ANTIBODIES | IMPERIAL CANCER RESEARCH TECHNOLOGY LTD (GB) | 1989-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030228673-A1 | Comprises genetically engineeered oxidoreductase having improved capability to oxidize secondary alcohols and/or D-glucose for use as quality control agents in dairy industry; biosensors in food processing | GALE, GALK1, G6PD | ACHE 1409/4885CHRM1 2258/4885ALDH1A1 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.